RedHill Biopharma (RDHL) EPS (Basic) (2016 - 2023)
Historic EPS (Basic) for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $0.09.
- RedHill Biopharma's EPS (Basic) rose 64459.57% to $0.09 in Q2 2023 from the same period last year, while for Jun 2024 it was $4.34, marking a year-over-year increase of 319766.85%. This contributed to the annual value of $0.01 for FY2023, which is 10833.33% up from last year.
- As of Q2 2023, RedHill Biopharma's EPS (Basic) stood at $0.09, which was up 64459.57% from -$0.05 recorded in Q1 2023.
- In the past 5 years, RedHill Biopharma's EPS (Basic) ranged from a high of $0.09 in Q2 2023 and a low of -$0.37 during Q4 2021
- Its 5-year average for EPS (Basic) is $0.0, with a median of $0.04 in 2019.
- In the last 5 years, RedHill Biopharma's EPS (Basic) crashed by 62857.14% in 2021 and then skyrocketed by 64459.57% in 2023.
- Over the past 5 years, RedHill Biopharma's EPS (Basic) (Quarter) stood at $0.03 in 2019, then soared by 133.33% to $0.07 in 2020, then crashed by 628.57% to -$0.37 in 2021, then surged by 35.14% to -$0.24 in 2022, then surged by 137.5% to $0.09 in 2023.
- Its last three reported values are $0.09 in Q2 2023, -$0.05 for Q1 2023, and -$0.24 during Q4 2022.